Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
From Lab to Market: Understanding the Evolutionary Journey and Market Landscape of Biochips
Biochips have emerged as indispensable tools in the healthcare sector, revolutionizing the way diseases are diagnosed, monitored, and treated. These miniature laboratories on a chip offer unparalleled efficiency, sensitivity, and speed in analyzing biological samples, making them invaluable in various medical applications. Their ability to simultaneously process multiple biomolecular interactions with high throughput has significantly enhanced diagnostic accuracy and therapeutic effectiveness, thereby improving patient outcomes and reducing healthcare costs. The growing benefits and importance of Biochips are evident in their ability to facilitate rapid and accurate disease diagnosis, personalized medicine,…
Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation
Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who had previously undergone at least one treatment and were not eligible for autologous stem cell transplant, had longer life expectancy when treated with Columvi® (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) compared to those treated…
ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo
ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous systemic treatment and have exhausted other available treatment options. With this approval, ENHERTU achieves a groundbreaking milestone as the premier therapy targeting HER2 across various tumor types, marking the first ADC to secure such a broad indication. ENHERTU, an ADC targeting HER2, was…